Keywords: Executive appointments, Bristol-Myers Squibb, Amgen

Executive appointments at Bristol-Myers Squibb and Amgen

Article | 21 October 2011

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) has announced a series of related changes within its senior management team following ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in